A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2-Reference-Cited by-同舟云学术

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Published:2020-08-07 Issue:6504 Volume:369 Page:650-655
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Chi Xiangyang¹^ORCID,Yan Renhong²^ORCID,Zhang Jun¹^ORCID,Zhang Guanying¹^ORCID,Zhang Yuanyuan²^ORCID,Hao Meng¹^ORCID,Zhang Zhe¹^ORCID,Fan Pengfei¹^ORCID,Dong Yunzhu¹^ORCID,Yang Yilong¹^ORCID,Chen Zhengshan¹^ORCID,Guo Yingying²^ORCID,Zhang Jinlong¹^ORCID,Li Yaning³^ORCID,Song Xiaohong¹^ORCID,Chen Yi¹^ORCID,Xia Lu²^ORCID,Fu Ling¹^ORCID,Hou Lihua¹^ORCID,Xu Junjie¹^ORCID,Yu Changming¹^ORCID,Li Jianmin¹^ORCID,Zhou Qiang²^ORCID,Chen Wei¹^ORCID

Affiliation:

1. Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.

2. Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake University, Hangzhou 310024, Zhejiang Province, China.

3. Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.

Abstract

Hitting SARS-CoV-2 in a new spot A key target for therapeutic antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the spike protein, a trimeric protein complex with each monomer comprising an S1 and an S2 domain that mediate binding to host cells and membrane fusion, respectively. In addition to the receptor binding domain (RBD), S1 has an N-terminal domain (NTD). In searching for neutralizing antibodies, there has been a focus on the RBD. Chi et al. isolated antibodies from 10 convalescent patients and identified an antibody that potently neutralizes the virus but does not bind the RBD. Cryo–electron microscopy revealed the epitope as the NTD. This NTD-targeting antibody may be useful to combine with RBD-targeting antibodies in therapeutic cocktails. Science , this issue p. 650

Funder

National Natural Science Foundation of China

Key RD Program of Zhejiang Province

SARS-CoV-2 emergency project of the Science and Technology Department of Zhejiang Province

Leading Innovative and Entrepreneur Team Introduction Program of Hangzhou

Special Research Program of Novel Coronavirus Pneumonia of Westlake University

National Key Research and Development Program of China Stem Cell and Translational Research

National Science and Technology Major Project of the Ministry of Science and Technology of China

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary